Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence

Clicks: 8
ID: 327889
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #329 of 383 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 383 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVE: Half of individuals with type 2 diabetes (T2D) also experience dyslipidaemia. In a phase IV clinical trial, fenofibrate was shown to reduce the risk of referable diabetic retinopathy (DR) comparing to placebo in people with background diabetic retinopathy (BDR). We aimed to generate comprehensive real-world evidence on the effects of fenofibrate on the risk of sight-threatening diabetic retinopathy (STDR) in individuals with T2D, compared with statins. METHODS: This propensity score-matched, prevalent new-user comparative effectiveness trial emulation study included adults (≥18 years) with T2D, receiving either statins or fenofibrate, as recorded in Clinical Practice Research Datalink (a UK primary care database) from 1 January 2000 to 30 June 2022. The primary outcome was incident STDR. After propensity score matching, competing risk Cox proportional hazard regression models were used to estimate the crude and adjusted hazard ratios (aHR) in both intention-to-treat (ITT) and per-protocol (PP) analyses. RESULTS: Data from 16,337 fenofibrate new users and their matched 25,764 statin users were included in this study. Participants were followed up for up to 12 years. Fenofibrate use was associated with a reduced risk of developing STDR (aHR: ITT 0.87, 95% CI 0.82-0.93; PP 0.80, 0.74-0.87) in comparison with the statin group. The results were consistent across sensitivity analysis and subgroups based on age, sex, ethnicity, and lipid levels. However, the protective effect was not observed in South Asians. CONCLUSIONS: Fenofibrate use was associated with a reduced risk of STDR in individuals with T2D in the real-world clinical practice. These fundings suggest that fenofibrate could be considered as a DR preventive therapy for individuals with T2D.
Reference Key
openalex_W7211900411 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Luyuan Tan, Jennifer Cooper, Krishna Gokhale, Christopher Sainsbury, Alastair K Denniston, Konstantinos A. Toulis, Francesca L. Crowe, Krishnarajah Nirantharakumar, Jingya Wang
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag367
URL
https://doi.org/10.1210/clinem/dgag367
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.